Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis

被引:72
作者
Nead, Kevin T. [1 ]
Sinha, Sumi [2 ,3 ]
Yang, David D. [2 ,3 ]
Nguyen, Paul L. [2 ,3 ]
机构
[1] Univ Penn, Perelman Ctr Adv Med, Perelman Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
关键词
Androgen deprivation therapy; Depression; Prostate cancer; Behavioral symptoms; Hormone therapy; QUALITY-OF-LIFE; MEN; ANXIETY; INTERMITTENT; IMPACT; SYMPTOMATOLOGY; SUPPRESSION; MORTALITY; SURVIVORS; SYMPTOMS;
D O I
10.1016/j.urolonc.2017.07.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There is increasing evidence that androgen deprivation therapy (ADT) may be associated with depression. Existing studies have shown conflicting results. Methods: PubMed, Web of Science, Embase, and PsycINFO were queried on April 5, 2017. Eligible studies were in English and reported depression among individuals with prostate cancer exposed to a course of ADT vs. a lesser-exposed group (e.g., any-ADT vs. no ADT and continuous ADT vs. intermittent ADT). We used the MOOSE statement guidelines and the Cochrane Review Group's data extraction template. Study quality was evaluated by Newcastle-Ottawa Scale criteria. We conducted a random-effects meta-analysis to calculate summary statistic risk ratios (RRs) and 95% CIs. Heterogeneity was quantified using the I-2 statistic and prespecified subgroup analysis. Small study effects were evaluated using Begg and Egger statistics. Results: A total of 1,128 studies were initially identified and evaluated. A meta-analysis of 18 studies among 168,756 individuals found that ADT use conferred a 41% increased risk of depression (RR = 1.41; 95% CI: 1.18-1.70; P < 0.001). We found a consistent strong statistically significant association when limiting our analysis to studies in localized disease (RR = 1.85; 95% CI: 1.20-2.85; P = 0.005) and those using a clinical diagnosis of depression (RR = 1.19; 95% CI: 1.08-1.32; P = 0.001). We did not find an association for continuous ADT with depression risk compared to intermittent ADT (RR = 1.00; 95% CI: 0.50-1.99; P = 0.992). There was no statistically significant evidence of small study effects. Statistically significant heterogeneity in the full analysis (I-2 = 80%; 95% CI: 69-87; P < 0.001) resolved when examining studies using a clinical diagnosis of depression (I-2 = 16%; 95% CI: 0-60; P = 0.310). Conclusion: The currently available evidence suggests that ADT in the treatment of prostate cancer is associated with an increased risk of depression. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:664.e1 / 664.e9
页数:9
相关论文
共 52 条
[1]   Partial Androgen Deficiency, Depression, and Testosterone Supplementation in Aging Men [J].
Amore, Mario ;
Innamorati, Marco ;
Costi, Sara ;
Sher, Leo ;
Girardi, Paolo ;
Pompili, Maurizio .
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2012, 2012
[2]  
[Anonymous], MODERN EPIDEMIOLOGY
[3]   Psychiatric treatment in men with prostate cancer - Results from a Nation-wide, population-based cohort study from PCBaSe Sweden [J].
Bill-Axelson, Anna ;
Garmo, Hans ;
Nyberg, Ullakarin ;
Lambe, Mats ;
Bratt, Ola ;
Stattin, Par ;
Adolfsson, Jan ;
Steineck, Gunnar .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) :2195-2201
[4]   Assessing and managing depression in the terminally ill patient [J].
Block, SD .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (03) :209-218
[5]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[6]   The association between prostate cancer and mood disorders: a nationwide population-based study in Taiwan [J].
Chen, Pan-Ming ;
Chen, San-Chi ;
Liu, Chia-Jen ;
Hung, Man-Hsin ;
Tsai, Chia-Fen ;
Hu, Yu-Wen ;
Chen, Mu-Hong ;
Shen, Cheng-Che ;
Su, Tung-Ping ;
Yeh, Chiu-Mei ;
Lu, Ti ;
Chen, Tzeng-Ji ;
Hu, Li-Yu .
INTERNATIONAL PSYCHOGERIATRICS, 2015, 27 (03) :481-490
[7]   The Impact of Physical Activity on Psychosocial Outcomes in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review [J].
Chipperfield, Kelly ;
Brooker, Joanne ;
Fletcher, Jane ;
Burney, Sue .
HEALTH PSYCHOLOGY, 2014, 33 (11) :1288-1297
[8]   Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy [J].
Chipperfield, Kelly ;
Fletcher, Jane ;
Millar, Jeremy ;
Brooker, Joanne ;
Smith, Robin ;
Frydenberg, Mark ;
Burney, Sue .
PSYCHO-ONCOLOGY, 2013, 22 (10) :2169-2176
[9]   Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder [J].
Chung, Shiu-Dong ;
Kao, Li-Ting ;
Lin, Herng-Ching ;
Xirasagar, Sudha ;
Huang, Chung-Chien ;
Lee, Hsin-Chien .
PLOS ONE, 2017, 12 (03)
[10]  
Couper JW, 2009, MED J AUSTRALIA, V190, pS86